patients with type 2 diabetes previously uncontrolled with  metformin or a sulfonylurea: A multinational, random-  ized, open-label, two-period, crossover noninferiority tri-  al. Clin Ther. 2007;29:2333-2348.  10. Riddle MC. Glycemic management of type 2 diabetes: An  emerging strategy with oral agents, insulins, and combi-  nations. Endocrinol Metab Clin North Am. 2005;34:77-98.  11. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects  on diabetes, obesity, cardiovascular risk factors and he-  patic biomarkers in patients with type 2 diabetes treated  for at least 3 years. CurrMed Res Opin. 2008;24:275-286.  12. Poon 3-, Nelson P, Shen L, et al. Exenatide improves gly-  cemic control and reduces body weight in subjects with  type 2 diabetes: A dose-ranging study. Diabetes Technol Ther.  2005;7:467-477.  13. Nelson P, Poon 3-, Guan X, et al. The incretin mimetic ex-  enatide as a monotherapy in patients with type 2 diabe-  tes. Diabetes Tecknol Tker. 2007;9:317-326.